Searchable abstracts of presentations at key conferences in endocrinology

ea0035p576 | Endocrine tumours and neoplasia | ECE2014

Correlation between atypical pituitary adenomas and Ki-67 Li: clinical and prognostic aspects

Chiloiro Sabrina , Bianchi Antonio , Giampietro Antonella , Iacovazzo Donato , Trapasso Barbara , Piacentini Serena , Tartaglione Linda , Lugli Francesca , De Marinis Laura

Introduction: In 2004, the WHO defined atypical pituitary adenomas (APAs) those with Ki-67 >3%, excessive p53 expression and increased mitotic activity. The usefulness of this classification is still controversial.Aim: To compare the clinical and prognostic features in a series of typical and atypical pituitary adenomas.Materials and methods: We retrospectively reviewed 343 consecutive PAs. APAs represented 18.7% of the cases. ...

ea0041ep928 | Pituitary - Clinical | ECE2016

Bone metabolism in acromegaly

Giampietro Antonella , Chiloiro Sabrina , Mormando Marilda , Bima Chiara , Bracaccia Maria Elena , Piacentini Serena , Tartaglione Linda , Iacovazzo Donato , Bianchi Antonio , De Marinis Laura

Aim: To evaluate calcium and bone metabolism in a monocentric series of acromegaly patients (pts), treated with pegvisomant (PEG) alone or in association to long acting somatostatine analogs.Patients and methods: All pts with at least 24 consecutive months PEG treatment (alone or in combination with SSA) were enrolled. All pts had been tested at least twice/year for biochemical acromegaly-disease evaluation and annually for calcium metabolism and for bon...

ea0035p937 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

IGF1 response to rhGH in adult GHD: role of GH receptor (GHR) isoforms

Bianchi Antonio , Tartaglione Linda , Giampietro Antonella , Milardi Domenico , Angelini Flavia , Mormando Marilda , Lugli Francesca , Piacentini Serena , Grande Giuseppe , Iacovazzo Donato , Chiloiro Sabrina , Pontecorvi Alfredo , Marinis Laura De

The IGF1 response to recombinant human growth hormone (rhGH) showed some individual variability and the responsible factors for this behavior remain unknown. Some studies have emphasized the possible role of isoforms of the GH receptor (GHR), showing conflicting results.Therefore, we investigated the possible influence of the isoforms of the GHR to the diagnosis of GHD and in determining adult hormone replacement therapy responsiveness.<p class="abst...

ea0032p103 | Bone and Osteoporosis | ECE2013

Efficacy and safety of the anabolic therapies in severe osteoporosis: experience of a team of endocrinologists and spine surgeons

Mormando Marilda , Fusco Alessandra , Pola Enrico , Piacentini Serena , Nasto Luigi Aurelio , Colangelo Debora , Chiloiro Sabrina , Bianchi Antonio , Pontecorvi Alfredo , De Marinis Laura

Anabolic therapies represent a major advance in the management of severe osteoporosis. Parathyroid hormone (PTH) and human recombinant PTH peptide 1–34 (Teriparatide) demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in patients with osteoporosis when given for 18–24 months. The intermittent administration of PTH or teriparatide stimulates osteoblastic function, improves bone architecture and has an additional analges...

ea0032p874 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Factors Affecting Prognosis in a Series of Acromegalic Patients

Fusco Alessandra , Bianchi Antonio , Giampietro Antonella , Iacovazzo Donato , Lugli Francesca , Chiloiro Sabrina , Piacentini Serena , Tartaglione Linda , Doglietto Francesco , Anile Carmelo , Maira Giulio , De Marinis Laura

Introduction: The main goal in the treatment of acromegaly is achieving biochemical and tumor mass control. Therapeutic options include surgery, medical treatment and, in selected cases, radiotherapy. A GH receptor (GHR) variant that differs for the genomic retention or exclusion (d3GHR) of exon 3 is present in about 50% of general population and its presence is related to a greater sensitivity to GH.Materials and methods: We describe a series of 118 pat...

ea0056p751 | Neuroendocrinology | ECE2018

Efficacy and safety of a combinated pasireotide lar, pegvisomant and cabergoline treatment in four cases of aggressive somatotrophinomas

Bima Chiara , Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Piacentini Serena , Milardi Domenico , Tartaglione Tommaso , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , Marinis Laura De

Introduction: A significant number of GH-secreting pituitary adenomas show an aggressive behavior, therefore, when uncontrolled acromegaly persists, a pharmaceutical combination may improve biochemical control, with reduction of disease morbidity and mortality. We aimed to describe the clinical features of four patients successfully treated with a pharmacological combination of pasireotide LAR, pegvisomant and cabergoline.Case reports: Acromegaly was dia...

ea0056p875 | Pituitary - Clinical | ECE2018

Efficacy of pasireotide lar in first line somatostatin analogue resistant acromegaly patients: experience from a large and single centre Italian cohort

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Tartaglione Tommaso , Bima Chiara , Piacentini Serena , Mirra Federica , Donfrancesco Federico , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , De Marinis Laura

Introduction: Pasireotide Lar is a new generation long-acting somatostatin multireceptor ligand, approved for the treatment of first line somatostatin analogue resistant patients. We aimed to review Pasireotide Lar efficacy data, in our series of patients affected by aggressive acromegaly.Patients: A retrospective longitudinal study was conducted on patients with aggressive acromegaly, resistant to first-line somatostatin analogues (SSA) and on treatment...

ea0037gp.28.01 | Endocrine tumours and neoplasia – NETS | ECE2015

Clinicopathologic features, treatments, and survival of patients with ectopic Cushing's syndrome from neuroendocrine tumours: data from an Italian multicentre study

Davi Maria Vittoria , Cosaro Elisa , Piacentini Serena , Reimondo Giuseppe , Albiger Nora , Arnaldi Giorgio , Faggiano Antongiulio , Mantovani Giovanna , Fazio Nicola , Grimaldi Franco , Mannelli Massimo , Giraldi Francesca Pecori , Martini Chiara , Ferone Diego , Campana Davide , Scaroni Carla , Terzolo Massimo , DeMarinis Laura , Francia Giuseppe

Introduction: Available literature on series of patients affected by ectopic Cushing’s syndrome (ECS) deriving from neuroendocrine tumours (NETs) is relatively scarce. This is the first Italian multicentre study regarding clinicopathologic features, modalities of treatment, and survival of patients with NETs and ECS.Patients and methods: Retrospective analysis of data from patients with ECS from NETs collected in 14 centres between 1986 and 2014, ob...